Outlook Therapeutics (OTLK) reported a quarterly loss of $0.09/share, in line with the Zacks Consensus. This is an improvement from a $0.44/share loss a year ago, suggesting reduced losses but no surprise versus expectations.
Outlook Therapeutics (OTLK) reported a quarterly loss of $0.09/share, in line with the Zacks Consensus. This is an improvement from a $0.44/share loss a year ago, suggesting reduced losses but no surprise versus expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
